SCHEMBL2393532

SCHEMBL2393532

COC(=O)C(F)c1ccccc1-c1ccccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
MAPT P10636 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 4/20 0.40
POLB P06746 2/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAP2K7 O14733 1/20 0.40
GMNN O75496 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
CDC25A P30304 1/20 0.40
CDC25B P30305 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890656 0.84 CES2 (0.42) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL2393913 0.81 MAPT (0.42) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL2391552 0.80 NPSR1 (0.47) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL2395411 0.78 NPSR1 (0.46) KMT2AMEN1MAPTNPSR1ALDH1A1
SCHEMBL28018515 0.76 KMT2A (0.48) KMT2AMEN1ALDH1A1POLBLMNA
SCHEMBL9890695 0.75 CHRM3 (0.41) KMT2AMEN1MAPTTACR3GPBAR1
SCHEMBL17724584 0.75 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1LMNAGAA
SCHEMBL19305429 0.75 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1LMNAGAA
SCHEMBL30885345 0.75 KMT2A (0.47) KMT2AALDH1A1CYP2C19
SCHEMBL27706318 0.75 KMT2A (0.47) KMT2AMEN1MAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885MEN1 1467/4885MAPT 3986/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885MEN1 1467/4885MAPT 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.